Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.60 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068580 | 0.89 | CYP4F2 (0.63) | CYP4F2CYP4A11PKMCES2KDM4E | |
| SCHEMBL21068992 | 0.78 | POLB (0.43) | CYP4F2CYP4A11TSHRPOLBNPSR1 | |
| SCHEMBL20730211 | 0.77 | CYP4F2 (0.97) | CYP4F2CYP4A11PKMKDM4ETSHR | |
| SCHEMBL23309176 | 0.75 | CYP4F2 (1.00) | CYP4F2CYP4A11PKMKDM4ETSHR | |
| SCHEMBL12112113 | 0.72 | CYP4F2 (0.38) | CYP4F2CYP4A11PKMKDM4ETSHR | |
| SCHEMBL20730190 | 0.71 | CYP4F2 (0.91) | CYP4F2CYP4A11PKMKDM4ETSHR | |
| SCHEMBL21068928 | 0.70 | CYP4F2 (0.47) | CYP4F2CYP4A11CES2TSHRTHRB | |
| SCHEMBL11655775 | 0.68 | CYP4F2 (0.49) | CYP4F2CYP4A11TSHRPOLBKMT2A | |
| SCHEMBL25247070 | 0.68 | CYP4F2 (0.59) | CYP4F2CYP4A11PKMCES2KDM4E | |
| SCHEMBL12634082 | 0.68 | CYP4F2 (0.35) | CYP4F2CYP4A11PKMKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | CYP4F2 107/4885CYP4A11 355/4885PKM 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.